JP2019509351A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509351A5
JP2019509351A5 JP2019500746A JP2019500746A JP2019509351A5 JP 2019509351 A5 JP2019509351 A5 JP 2019509351A5 JP 2019500746 A JP2019500746 A JP 2019500746A JP 2019500746 A JP2019500746 A JP 2019500746A JP 2019509351 A5 JP2019509351 A5 JP 2019509351A5
Authority
JP
Japan
Prior art keywords
therapy
administration
active substance
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019500746A
Other languages
English (en)
Japanese (ja)
Other versions
JP7048571B2 (ja
JP2019509351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/023676 external-priority patent/WO2017165571A1/en
Publication of JP2019509351A publication Critical patent/JP2019509351A/ja
Publication of JP2019509351A5 publication Critical patent/JP2019509351A5/ja
Priority to JP2022047991A priority Critical patent/JP7528143B2/ja
Application granted granted Critical
Publication of JP7048571B2 publication Critical patent/JP7048571B2/ja
Priority to JP2024118592A priority patent/JP2024156736A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019500746A 2016-03-22 2017-03-22 毒性を予防または改善するための早期介入法 Active JP7048571B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022047991A JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662311906P 2016-03-22 2016-03-22
US62/311,906 2016-03-22
US201662417287P 2016-11-03 2016-11-03
US62/417,287 2016-11-03
US201662429722P 2016-12-02 2016-12-02
US62/429,722 2016-12-02
PCT/US2017/023676 WO2017165571A1 (en) 2016-03-22 2017-03-22 Early intervention methods to prevent or ameliorate toxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022047991A Division JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法

Publications (3)

Publication Number Publication Date
JP2019509351A JP2019509351A (ja) 2019-04-04
JP2019509351A5 true JP2019509351A5 (https=) 2020-04-30
JP7048571B2 JP7048571B2 (ja) 2022-04-05

Family

ID=58609964

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019500746A Active JP7048571B2 (ja) 2016-03-22 2017-03-22 毒性を予防または改善するための早期介入法
JP2022047991A Active JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A Pending JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022047991A Active JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A Pending JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Country Status (13)

Country Link
US (5) US11518814B2 (https=)
EP (3) EP4545143A3 (https=)
JP (3) JP7048571B2 (https=)
KR (1) KR20190021200A (https=)
CN (1) CN109476743A (https=)
AU (2) AU2017238218B2 (https=)
BR (1) BR112018069251A2 (https=)
CA (1) CA3018588A1 (https=)
ES (1) ES2907557T3 (https=)
MA (2) MA71266A (https=)
MX (1) MX2018011480A (https=)
RU (1) RU2018136877A (https=)
WO (1) WO2017165571A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
EP4012415A3 (en) 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
KR20190021200A (ko) 2016-03-22 2019-03-05 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 독성을 예방 또는 경감시키기 위한 조기 개재 방법
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
BR112019011065A2 (pt) * 2016-12-03 2019-10-01 Juno Therapeutics Inc métodos para determinação da dosagem de células t car
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
US12163952B2 (en) 2017-02-27 2024-12-10 Juno Therapeutics, Inc. Determining toxicity risk in CAR T-cell therapy
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US20210198372A1 (en) * 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
IL311485B1 (en) 2018-02-16 2026-01-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
CN111989344A (zh) * 2018-03-09 2020-11-24 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
WO2019170845A1 (en) * 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
WO2019195823A1 (en) * 2018-04-06 2019-10-10 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
WO2021028469A1 (en) * 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
ES2970382T3 (es) * 2019-08-14 2024-05-28 Rigel Pharmaceuticals Inc Método para bloquear o mejorar el síndrome de liberación de citocinas
AU2021217003A1 (en) 2020-02-04 2022-09-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-dinitrophenol chimeric antigen receptors
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
WO2022072515A1 (en) * 2020-09-29 2022-04-07 Washington University Methods to determine risk of neurotoxicity
WO2022125670A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
RS67455B1 (sr) 2021-05-03 2025-12-31 Incyte Corp Inhibitori jak1 puta za lečenje prurigo nodularisa

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US265209A (en) 1882-09-26 Automatic feeder for perforators
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2007147623A2 (en) * 2006-06-22 2007-12-27 Cellact Pharma Gmbh A novel target in the treatment of cytokine release syndrome
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
CN103249742B (zh) * 2010-09-16 2017-04-12 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
LT4461308T (lt) * 2012-07-13 2025-06-10 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo valdymas
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US11512289B2 (en) * 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
KR20190021200A (ko) 2016-03-22 2019-03-05 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 독성을 예방 또는 경감시키기 위한 조기 개재 방법
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor

Similar Documents

Publication Publication Date Title
JP2019509351A5 (https=)
Shimba et al. Pleiotropic effects of glucocorticoids on the immune system in circadian rhythm and stress
De Waele et al. A systematic review on poly (I: C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
JP2024156736A5 (https=)
Silverman et al. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection
Canna et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
Shoenfeld et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008
Mesquida et al. Interleukin-6 blockade in ocular inflammatory diseases
JP2021102644A5 (https=)
AU2017238218A1 (en) Early intervention methods to prevent or ameliorate toxicity
Piccinni et al. Medroxyprogesterone acetate decreases Th1, Th17, and increases Th22 responses via AHR signaling which could affect susceptibility to infections and inflammatory disease
JP2019504892A5 (https=)
Kasapçopur et al. Treatment in juvenile rheumatoid arthritis and new treatment options
JP2020530831A5 (https=)
Stallmach et al. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo
JP2017523187A5 (https=)
EP3193894A1 (en) Use of cord blood plasma to treat nk cell-mediated diseases and ifn- mediated diseases
Bellmann et al. A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model
Everaerdt et al. Recombinant IL-1 receptor antagonist protects against TNF-induced lethality in mice.
Khan et al. Interleukin inhibitors and the associated risk of candidiasis
JPWO2020250915A5 (https=)
Spies et al. Prednisone chronotherapy
Jain et al. Radiation therapy as a bridging strategy for refractory diffuse large B cell lymphoma patients awaiting CAR T manufacturing of axicabtagene ciloleucel
IL321878A (en) Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
Schuler et al. Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study